Lapatinib
Lapatinib is a pharmaceutical drug with 144 clinical trials. Currently 3 active trials ongoing. Historical success rate of 73.6%.
Success Metrics
Based on 92 completed trials
Phase Distribution
Phase Distribution
44
Early Stage
74
Mid Stage
23
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
70.8%
92 of 130 finished
29.2%
38 ended early
3
trials recruiting
144
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Molecular Profiling of Advanced Soft-tissue Sarcomas
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Clinical Trials (144)
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Molecular Profiling of Advanced Soft-tissue Sarcomas
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 144